Taysha Gene Therapies Inc
TSHAHealthcare|Biotechnology|USA
$6.34
-0.23 (-3.50%)
Tangible Book
$0.74
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07480564 Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome | Rett Syndrome | P3 | Recruiting | 3 | Open-label | — |
| NCT05606614 A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) | Rett Syndrome | P3 | Active | 17 | Single-blind | — |
| NCT04798235 First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis | Infantile GM2 Gangliosidosis (Disorder) | P1P2 | Active | 3 | Open-label | TSHA-101 |
| NCT06152237 Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) | Rett Syndrome | P1P2 | Active | 6 | RCT, Open-label | — |
| NCT05277363 A Study of the Natural Course of SURF1 Deficiency | Leigh Syndrome | Withdrawn | — | — | — |